Table 3.

Clinical characteristics of patients at the end of follow-up (n = 228).

	Mean (standard deviation) or Frequency (%)			p-value
Variable	Total (n = 228)	NTP (n = 114; 50%)	TP (n = 114; 50%)
Digestive form	15 (6.6)	9 (7.9)	6 (5.3)	0.42
Arterial Hypertension	73 (32.0)	45 (39.5)	28 (24.6)	0.02
Diabetes Mellitus	28 (12.3)	15 (13.2)	13 (11.4)	0.69
Dislipidemia	76 (33.3)	49 (43.0)	27 (23.7)	0.002
Non-chagasic cardiomyopathy	6 (2.6)	3 (2.6)	3 (2.6)	1.00
Other comorbidities*	38 (16.7)	26 (22.8)	12 (10.5)	0.01
Clinical presentation of Chagas disease
Indeterminate	195 (85.5)	90 (78.9)	105 (92.1)	0.02
Cardiac stage A	23 (10.1)	16 (14.0)	7 (6.1)
Cardiac stage B1	5 (2.2)	3 (2.6)	2 (1.8)
Cardiac stage B2	0 (0.0)	0 (0.0)	0 (0.0)
Cardiac stage C	5 (2.2)	5 (4.4)	0 (0.0)
CD specific ECG abnormalities	34 (14.9)	25 (21.9)	9 (7.9)	0.003
Second or third-degree right bundle-branch block	14 (6.1)	11 (9.7)	3 (2.6)	0.03
Frequent atrial or ventricular premature beats	5 (2.2)	3 (2.6)	2 (1.8)	0.65
Primary ST-T wave abnormalities	13 (5.7)	11 (9.7)	2 (1.8)	0.01
Electrical inactive area	4 (1.8)	2 (1.8)	2 (1.8)	1.00
Second or three-degree left bundle-branch block	2 (0.9)	1 (0.9)	1 (0.9)	1.00
Atrial flutter	1 (0.4)	1 (0.9)	0 (0.0)	0.32
Atrial tachycardia	1 (0.4)	1 (0.9)	0 (0.0)	0.32
Echocardiogram abnormalities (n = 172)	56 (32.6)	40 (42.1)	16 (20.8)	0.003
Diastolic dysfunction	42 (24.4)	32 (33.7)	10 (13.0)	0.002
Segmental dysfunction	19 (11.1)	14 (14.8)	5 (6.5)	0.09
Global systolic dysfunction	13 (7.6)	10 (10.5)	3 (3.9)	0.10
Serological cure	13 (5.7)	0 (0.0)	13 (11.4)	<0.001

^⁎Other comorbidities included cancer, asthma, chronic obstructive pulmonary disease, hypothyroidism, depression, alcohol abuse, and co-infection (HIV, HTLV, and viral hepatitis).